Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
AcelRx Pharmaceuticals of Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Launching an initial public offering (IPO) the same week the stock market plunged 1,190 in a single day may just be bad luck, but it does not seem to have negatively affected Passage Bio’s IPO.
Although there were some deals announced at the ongoing J.P. Morgan Healthcare Conference, biotech stocks appeared to slide slightly at the overall lack of business transactions, at least during the first day or two.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.
Mallinckrodt Plc hired restructuring firms and may choose to seek bankruptcy protection, Bloomberg reported, sending the drugmaker’s shares down 40 percent.
Elanco Animal Health agreed to buy Bayer’s veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second-largest maker of medicines for pets and livestock and expanding Elanco’s reach online.